Moody Aldrich Partners LLC Purchases 44,606 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Moody Aldrich Partners LLC increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 80.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,340 shares of the company’s stock after buying an additional 44,606 shares during the quarter. Moody Aldrich Partners LLC owned 0.21% of Amphastar Pharmaceuticals worth $4,870,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC bought a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $11,070,000. Guidance Capital Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 6.3% during the third quarter. Guidance Capital Inc. now owns 10,388 shares of the company’s stock valued at $528,000 after purchasing an additional 618 shares during the period. Retirement Guys Formula LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at approximately $203,000. Raymond James & Associates boosted its stake in shares of Amphastar Pharmaceuticals by 1.7% during the third quarter. Raymond James & Associates now owns 116,677 shares of the company’s stock valued at $5,662,000 after purchasing an additional 1,958 shares during the period. Finally, nVerses Capital LLC boosted its stake in shares of Amphastar Pharmaceuticals by 18.2% during the third quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock valued at $126,000 after purchasing an additional 400 shares during the period. Institutional investors own 65.09% of the company’s stock.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the transaction, the executive vice president now owns 118,388 shares in the company, valued at approximately $5,724,059.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the transaction, the executive vice president now owns 118,388 shares in the company, valued at approximately $5,724,059.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the transaction, the director now owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,383 shares of company stock worth $1,524,123. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Trading Up 2.8 %

AMPH stock traded up $1.39 on Thursday, reaching $51.22. The company’s stock had a trading volume of 51,199 shares, compared to its average volume of 394,292. The business has a fifty day simple moving average of $47.71 and a two-hundred day simple moving average of $43.36. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The firm has a market cap of $2.50 billion, a PE ratio of 17.24, a PEG ratio of 0.88 and a beta of 0.83. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The company had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. As a group, research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AMPH. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, October 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.